• Difficulty of swallowing (Dysphasia) affects about 85% of ALS patients
  • Biggest fears that people with ALS have is choking
  • First line therapy comes in oral dosage forms
  • Risk of food/liquid aspiration into the lungs is a present danger to ALS patients

NT-401 provides a non-oral, patient-friendly delivery option for individuals with neurodegenerative diseases where swallowing impairment limits conventional medication use.